Maureen M. Hattersley

Author

AstraZeneca (United States)ORCID

Also Known As

M. Hattersley, M. Mertens Hattersley, Maureen Hattersley, Maureen M. Hattersley, Maureen Mertens Hattersley

130

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United States)AstraZeneca (United Kingdom)The University of Texas MD Anderson Cancer Center Tennessee Oncology Sarah Cannon

About

Maureen M. Hattersley is an author at AstraZeneca (United States) specializing in medicine, drug discovery, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	732
2	Natural Sciences	3	3	207
3	Engineering	2	2	331
4	Biochemistry	2	2	107
5	Health Sciences	1	1	23

Maureen M. Hattersley

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency Chaoyang Sun, Jun‐Jie Yin, Yong Fang, Cancer Cell Homologous Recombination DeficiencyEngineeringMolecular BiologySynthetic BiologyRecombination Dynamic	2018	295
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao, Molecular Cancer Therapeutics Azd5153 ExposurePathologyPharmacotherapyTumor BiologyMyeloid Neoplasia	2016	147
Discovery of a Novel Class of Dimeric Smac Mimetics as Potent IAP Antagonists Resulting in a Clinical Candidate for the Treatment of Cancer (AZD5582) Edward J. Hennessy, Ammar Adam, Brian Aquila, Journal of Medicinal Chemistry Compound 14ApoptosisCell DeathPharmacotherapyTumor Biology	2013	112
PKC-θ-Deficient Mice Are Protected from Th1-Dependent Antigen-Induced Arthritis Aileen M. Healy, Elena S. Izmailova, Michael Fitzgerald, The Journal of Immunology ImmunologyImmune RegulationPathologyMusculoskeletal ResearchInflammatory Arthritis	2006	104
BRD4 facilitates replication stress-induced DNA damage response Jingwen Zhang, Austin Dulak, Maureen M. Hattersley, Oncogene ChromatinGenome InstabilityDna DamageNatural SciencesGenetics	2018	100
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i> -Mutant Non–Small Cell Lung Cancer Dennis O. Adeegbe, Shengwu Liu, Maureen M. Hattersley, Cancer Immunology Research	2018	100
Inhibition of the Hedgehog Pathway Targets the Tumor-Associated Stroma in Pancreatic Cancer Rosa F. Hwang, Todd T. Moore, Maureen M. Hattersley, Molecular Cancer Research	2012	97
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3<i>R</i>)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153) Robert H. Bradbury, Rowena Callis, Gregory R. Carr, Journal of Medicinal Chemistry Pharmaceutical ScienceChemoprevention StrategyOrganic ChemistryPharmacotherapyPharmaceutical Chemistry	2016	85
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models Alwin G. Schuller, Evan Barry, Rhys D.O. Jones, Clinical Cancer Research	2015	78
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Clinical Cancer Research	2022	67

Page 1